Ethnic Variations in Antidepressant Response

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00047671

Enrollment

400

Registered

2002-10-16

Start date

2002-06-30

Completion date

2006-11-30

Last updated

2009-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depressive Disorder

Brief summary

This 11-week study aims to determine how genetic factors affect the way African Americans and Caucasians with major depression respond to antidepressant medication \[citalopram (Celexa®)\].

Detailed description

Depressed patients vary substantially in their responses to antidepressants. Genetic factors may account for a large part of these differences in response. This study will include both African Americans and Caucasians to examine the role of genetic factors in treatment response. Participants receive citalopram (Celexa) for 8 weeks and a placebo for 1 week. Visits occur once a week for 11 weeks. A variety of interviews, scales, tests, and questionnaires are used to assess participants.

Interventions

DRUGCitalopram

PDA Approved antidepressant

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* DSM-IV criteria for Major Depression * African-American or Caucasian ethnic background (both parents and 3 out of 4 grandparents)

Exclusion criteria

* Schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression, or bipolar disorder * Current drug abuse or history of drug abuse within the past 6 months * Unstable medical or neurological conditions that interfere with the treatment of depression * Allergy to citalopram * Failure to respond to adequate citalopram drug trial (40 mg for at least 6 weeks) * Seizure disorder * Pregnancy * Psychotropic medications, including antidepressants and neuroleptics * Suicidal ideation or other safety issues * Fluoxetine (Prozac) or MAOIs (Nardil, Parnate) in the last 2 months * Ongoing cognitive behavioral therapy or intensive psychotherapy. General talk therapy is acceptable

Design outcomes

Primary

Measure	Time frame
Hamilton Rating Scale for Depression	Measured weekly for 11 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026